Close this search box.

Shinobi’s immune-protected cell therapies; plus Emugen, AZ and more

ARTICLE | Discovery & Translation

BioCentury’s roundup of translational innovations

By Danielle Golovin, Biopharma Analyst

November 10, 2023 11:59 PM UTC

Shinobi Therapeutics and collaborators at the University of California San Francisco described in Cell Stem Cell a method to prevent innate immune cell killing of allogeneic cell therapies. The authors, including  Sana Biotechnology Inc. (NASDAQ:SANA) scientific founder Sonja Schrepfer, showed immune checkpoint engagers that activate inhibitory innate immune cell receptors TIM3 and SIRPA protected engineered human leukocyte antigen (HLA)-depleted induced pluripotent stem cell-derived endothelial cells from killing by NK cells and macrophages. Combining the engagers with a truncated CD64, which evades cytotoxic IgG, allowed for complete immune evasion.

UCSF filed patent applications that cover the work…